MGUS/MM Awareness and Genetics Insights Campaign (MAGIC) Screening Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Non-Interventional Study.
- Who it may be relevant to
- Registry conditions: Monoclonal Gammopathy of Undetermined Significance. Basic parameters: from 40 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Monoclonal Gammopathy of Undetermined Significance (MGUS) /Myeloma Awareness and Genetic Insights Campaign (MAGIC) Screening Study
Overview
This study is being done to screen adults for MGUS and to better understand the genetic and immune factors linked to this condition. Monoclonal gammopathy of undetermined significance or MGUS is a condition where an abnormal immune protein is found in the blood. MGUS is not cancer. In some people, it slowly develops into a blood cancer called multiple myeloma. MGUS occurs in people from all backgrounds. Researchers hope to use the information from this study to improve knowledge, early detection, and future care for everyone.
Detailed description
PRIMARY OBJECTIVE:
I. To determine the prevalence of monoclonal gammopathies (MGUS, Smoldering and Multiple Myeloma) across ancestrally diverse populations in Minnesota, with prespecified, ancestry-informed analyses within East African, West African, Afro-Caribbean, and Non-Hispanic White groups.
OUTLINE: This is an observational study.
Participants undergo medical chart review and blood sample collection, as well as complete a questionnaire on study. Participants who test positive for MGUS are notified, along with their primary care physician, so that the necessary follow up and referral is provided as clinically indicated.
Interventions
- Other Non-Interventional Study
Non-interventional study
Primary outcome measures
- Prevalence of monoclonal gammopathies across ancestrally diverse populations [Time frame: Up to 10 years]
Eligibility criteria
Inclusion criteria
- Adults ≥ 40 years
- Willing and able to review, understand, and provide consent before starting any study-specific procedures
- Ability to complete questionnaire(s) by themselves or with assistance
Exclusion criteria
- Pregnant women
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- Mayo Clinic in Rochester — Rochester
Identifiers
NCT: NCT06472830 · 23-008956